HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL
Phase 2 Completed
10 enrolled 7 charts
RESMAIN
Phase 2 Completed
201 enrolled
PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma
Phase 2 Completed
9 enrolled 9 charts
Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.
Phase 2 Completed
25 enrolled
Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.
Phase 2 Completed
22 enrolled
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
Phase 1/2 Completed
58 enrolled 18 charts
FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
Phase 3 Completed
169 enrolled 13 charts
A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat
Phase 1 Completed
5 enrolled
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies
Phase 1/2 Completed
81 enrolled
Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL)
Phase 1 Completed
5 enrolled
ALCANZA
Phase 3 Completed
131 enrolled 24 charts
Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL
Phase 1 Completed
66 enrolled
PROVe
Completed
300 enrolled 7 charts
Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Phase 1 Completed
55 enrolled
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Phase 1 Completed
34 enrolled
Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)
Phase 4 Completed
59 enrolled 17 charts
Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)
Phase 2 Completed
74 enrolled
A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)
Phase 2 Completed
32 enrolled
SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma
Phase 1 Completed
20 enrolled
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Phase 1 Completed
27 enrolled
A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma
Phase 2 Completed
25 enrolled
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
Phase 3 Completed
130 enrolled 9 charts
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
Phase 2 Completed
100 enrolled
Forodesine in the Treatment of Cutaneous T-Cell Lymphoma
Phase 2 Completed
144 enrolled
Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients
Phase 4 Completed
195 enrolled
Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients
Phase 4 Completed
86 enrolled